Lim Jacqueline Kyungah, Carabali Mabel, Lee Jung-Seok, Lee Kang-Sung, Namkung Suk, Lim Sl-Ki, Ridde Valéry, Fernandes Jose, Lell Bertrand, Matendechero Sultani Hadley, Esen Meral, Andia Esther, Oyembo Noah, Barro Ahmed, Bonnet Emmanuel, Njenga Sammy M, Agnandji Selidji Todagbe, Yaro Seydou, Alexander Neal, Yoon In-Kyu
Global Dengue and Aedes-transmitted Diseases Consortium, International Vaccine Institute, Gwanak-gu, The Republic of Korea.
Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
BMJ Open. 2018 Jan 21;8(1):e017673. doi: 10.1136/bmjopen-2017-017673.
Dengue is an important and well-documented public health problem in the Asia-Pacific and Latin American regions. However, in Africa, information on disease burden is limited to case reports and reports of sporadic outbreaks, thus hindering the implementation of public health actions for disease control. To gather evidence on the undocumented burden of dengue in Africa, epidemiological studies with standardised methods were launched in three locations in Africa.
In 2014-2017, the Dengue Vaccine Initiative initiated field studies at three sites in Ouagadougou, Burkina Faso; Lambaréné, Gabon and Mombasa, Kenya to obtain comparable incidence data on dengue and assess its burden through standardised hospital-based surveillance and community-based serological methods. Multidisciplinary measurements of the burden of dengue were obtained through field studies that included passive facility-based fever surveillance, cost-of-illness surveys, serological surveys and healthcare utilisation surveys. All three sites conducted case detection using standardised procedures with uniform laboratory assays to diagnose dengue. Healthcare utilisation surveys were conducted to adjust population denominators in incidence calculations for differing healthcare seeking patterns. The fever surveillance data will allow calculation of age-specific incidence rates and comparison of symptomatic presentation between patients with dengue and non-dengue using multivariable logistic regression. Serological surveys assessed changes in immune status of cohorts of approximately 3000 randomly selected residents at each site at 6-month intervals. The age-stratified serosurvey data will allow calculation of seroprevalence and force of infection of dengue. Cost-of-illness evaluations were conducted among patients with acute dengue by Rapid Diagnostic Test.
By standardising methods to evaluate dengue burden across several sites in Africa, these studies will generate evidence for dengue burden in Africa and data will be disseminated as publication in peer-review journals in 2018.
登革热在亚太地区和拉丁美洲地区是一个重要且有充分文献记载的公共卫生问题。然而,在非洲,关于疾病负担的信息仅限于病例报告和散发性疫情报告,这阻碍了实施疾病控制的公共卫生行动。为了收集非洲未记录的登革热负担证据,在非洲的三个地点开展了采用标准化方法的流行病学研究。
2014 - 2017年期间,登革热疫苗倡议组织在布基纳法索瓦加杜古、加蓬兰巴雷内和肯尼亚蒙巴萨的三个地点开展了实地研究,以获取登革热的可比发病率数据,并通过标准化的基于医院的监测和基于社区的血清学方法评估其负担。通过实地研究获得了登革热负担的多学科测量数据,这些研究包括基于医疗机构的被动发热监测、疾病成本调查、血清学调查和医疗保健利用调查。所有三个地点都使用标准化程序和统一的实验室检测方法进行病例检测以诊断登革热。开展医疗保健利用调查是为了针对不同的就医模式调整发病率计算中的人口分母。发热监测数据将有助于计算特定年龄发病率,并使用多变量逻辑回归比较登革热患者和非登革热患者的症状表现。血清学调查每隔6个月评估每个地点约3000名随机选择居民队列的免疫状态变化。按年龄分层的血清学调查数据将有助于计算登革热的血清阳性率和感染强度。通过快速诊断检测对急性登革热患者进行疾病成本评估。
通过标准化评估非洲多个地点登革热负担的方法,这些研究将为非洲的登革热负担提供证据,相关数据将于2018年作为同行评议期刊上的出版物发布。